Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses - Summary - MDSpire

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • By

  • Debra Nana Yeboa

  • Benjamin T. Whitfield

  • Ruitao Lin

  • Chinenye Lynette Ejezie

  • Todd A. Swanson

  • Thomas H. Beckham

  • Chenyang Wang

  • Brian De

  • Subha Perni

  • Martin C. Tom

  • Jing Li

  • Susan L. McGovern

  • Rebecca Harrison

  • Nazanin K. Majd

  • Vinay K. Puduvalli

  • Ashley E. Aaroe

  • Monica Loghin

  • Barbara J. O’Brien

  • Anuj D. Patel

  • Chirag B. Patel

  • Jeffrey S. Wefel

  • Ceylan Altintas Taslicay

  • Maria Gule-Monroe

  • Arnold C. Paulino

  • Mary Frances McAleer

  • David R. Grosshans

  • Amol J. Ghia

  • Wen Jiang

  • Caroline Chung

  • Moshe Maor

  • Cheng-Han Yang

  • Maria A. Gubbiotti

  • Carlos Kamiya-Matsuoka

  • Leomar Y. Ballester

  • Shiao-Pei Weathers

  • Jason T. Huse

  • November 5, 2025

  • 0 min

Share

Objective:

To evaluate outcomes for molecular glioblastoma (molGBM) with treatment intensification compared to historical controls, specifically focusing on overall survival (OS) and other relevant clinical outcomes.

Key Findings:
  • Preliminary findings indicate a critical need for risk stratification of molGBM based on RT outcomes and biomolecular data, which may influence treatment decisions.
  • Median overall survival for molGBM is estimated to be higher than that for histGBM, despite similar overall survival rates, suggesting different underlying biology.
  • Differences in survival within the molGBM population suggest significant underlying heterogeneity that warrants further investigation.
Interpretation:

The study underscores the necessity for more rigorous analysis and the establishment of standard-of-care management principles for molGBM, given its distinct characteristics and treatment responses.

Limitations:
  • Ongoing study with preliminary data; final results pending, which may limit the generalizability of current findings.
  • Limited sample size and potential biases in historical control comparisons may affect the robustness of conclusions drawn.
Conclusion:

Establishing effective treatment protocols for molGBM requires further investigation into its unique biological and clinical characteristics, emphasizing the need for tailored approaches.

Original Source(s)

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • by Debra Nana Yeboa, Benjamin T. Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A. Swanson, Thomas H. Beckham, Chenyang Wang, Brian De, Subha Perni, Martin C. Tom, Jing Li, Susan L. McGovern, Rebecca Harrison, Nazanin K. Majd, Vinay K. Puduvalli, Ashley E. Aaroe, Monica Loghin, Barbara J. O’Brien, Anuj D. Patel, Chirag B. Patel, Jeffrey S. Wefel, Ceylan Altintas Taslicay, Maria Gule-Monroe, Arnold C. Paulino, Mary Frances McAleer, David R. Grosshans, Amol J. Ghia, Wen Jiang, Caroline Chung, Moshe Maor, Cheng-Han Yang, Maria A. Gubbiotti, Carlos Kamiya-Matsuoka, Leomar Y. Ballester, Shiao-Pei Weathers, Jason T. Huse

  • November 5, 2025

Related Content

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen